Effects of Paroxetine and Sertraline on Low-Density Lipoprotein Cholesterol
- 126 Downloads
Background: Antidepressant use in US adults increased 3-fold from 2.5% in 1988–94 to 8.1% in 1999–2002, based on National Health and Nutrition Examination Surveys. As the use of antidepressants increases, a comprehensive understanding of the potential health risks that may be associated with their use becomes increasingly important.
Objective: This study evaluated the effects of paroxetine and sertraline on low-density lipoprotein cholesterol (LDL-C).
Study Design: An observational cohort study (1997–2004) of adults who had taken paroxetine or sertraline for at least 60 continuous days and had ≥2 LDL-C values measured during the study period, one while taking and one while not taking paroxetine or sertraline. A total of 13 634 LDL-C values clustered within 2682 patients were studied.
Methods: We conducted mixed model regression analyses to quantify the relationship between antidepressant use and LDL-C values.
Results: The number of days taking paroxetine (β = 0.0045; 95% CI 0.0018, 0.0073) and sertraline (β = 0.0074; 95% CI 0.0054, 0.0093) prior to the LDL-C test were related to higher LDL-C values, after accounting for age, sex, year LDL-C was tested, co-morbidity, depression and lipid medication. The number of days that had passed since exposure to paroxetine (β =−0.0013; 95% CI −0.0020, −0.00061) or sertraline (β = −0.00093; 95% CI −0.016, −0.00022) were related to lower LDL-C values. The significant interaction between exposure to an antidepressant and taking a lipid medication demonstrates that the increase in LDL-C values associated with antidepressant use is ameliorated among patients who were taking a lipid medication when LDL-C was measured.
Conclusion: Our study showed that long-term use of paroxetine or sertraline may have a measurable adverse impact on cardiovascular risk in adults. Clinical strategies should be used to address cardiovascular risk while maintaining effective treatment of major depression. In light of these findings, attention to LDL-C values should accompany antidepressant use.
KeywordsCardiovascular Risk Paroxetine Sertraline Antidepressant Medication Depression Diagnosis
The Health Partners Research Foundation provided funding for this study. The authors have no conflicts of interest that are directly relevant to the content of this study.
- 7.Institute for Clinical Systems Improvement (ICSI). Health care guideline: major depression in adults for mental health care. Bloomington (MN): Institute for Clinical Systems Improvement, 2004 MayGoogle Scholar
- 8.National Heart, Lung, and Blood Institute Working Group on Insomnia. Insomnia: assessment and management in primary care. Am Fam Physician 1999 Jun; 59(11): 3029–38Google Scholar
- 10.Liebowitz MR, Mangano RM. Venlafaxine XR in generalized social anxiety disorder. 42nd Annual New Clinical Drug Evaluation Unit Meeting; 2002 Jun 10–13; Boca Raton (FL)Google Scholar
- 13.Prozac [package insert]. Indianapolis (IN): Eli Lilly and Company, 2001Google Scholar
- 14.Remeron [package insert]. West Orange (NJ): CIMA Labs Inc., 2002Google Scholar
- 15.Serzone [package insert]. Princeton (NJ): Bristol-Myers Squibb Company, 2002Google Scholar
- 16.Lexapro [package insert]. St Louis (MO): Forest Pharmaceuticals, Inc., 2004Google Scholar
- 17.Zoloft [package insert]. New York: Roerig a Division of Pfizer Inc., 2004Google Scholar
- 18.Effexor [package insert]. Philadelphia (PA): Wyeth Pharmaceuticals, Inc., 2004Google Scholar
- 19.National Institutes of Health. NIH halts use of COX-2 inhibitor in large cancer prevention trial [media release]. 2004 Dec 17 [online]. Available from URL: http://www.nih.gov/news/pr/dec2004/od-17.htm [Accessed 2009 Aug 19]
- 25.Institute for Clinical Systems Improvement. Health care guideline: preventive services for adults. 9th ed. Bloomington (MN): Institute for Clinical Systems Improvement, 2003Google Scholar
- 26.Institute for Clinical Systems Improvement. Health care guideline: lipid screening in adults. 8th ed. Bloomington (MN): Institute for Clinical Systems Improvement, 2004Google Scholar
- 28.National Center for Health Statistics. International classification of disease. 9th revision, clinical modification [online]. Available from URL http://www.cdc.gov/nchs/about/otheract/icd9/acticd9.htm [Accessed 2009 Jul 10]
- 30.Rush WA, O’Connor PJ, Goodman MJ. Validation of a modified Charlson score for using health plan claims data. Minnesota Health Services Research Conference; 2000 Feb 22; Minneapolis (MN)Google Scholar
- 31.Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986 Nov 28; 256(20): 2823–8PubMedCrossRefGoogle Scholar
- 32.Paxil [package insert]. Research Triangle Park (NC): GlaxoSmithKline, 2004Google Scholar
- 36.The Lipid Research Clinics Coronary Primary Prevention Trial results I: reduction in incidence of coronary heart disease. JAMA 1984 Jan 20; 251 (3): 351-64Google Scholar
- 37.The Lipid Research Clinics Coronary Primary Prevention Trial results II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984 Jan 20; 251 (3): 365-74Google Scholar
- 39.Law MR. Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. Eur Heart J 1999; 1Suppl. S: S3–8Google Scholar
- 42.Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000; 61 Suppl. 11: 37–41Google Scholar